Adagene Inc.
NNASDAQ:ADAGCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pei Zhi Luo
- Full Time Employees
- 128
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building C14 Suzhou JS China 215123
- IPO Date
- Feb 9, 2021
- CIK
- 0001818838
- Website
- adagene.com
- Similar Companies
- Business
- Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company that develops novel antibody-based cancer immunotherapies using proprietary technologies including NEObody for targeting unique epitopes with novel mechanisms of action; SAFEbody for precision masking and tumor microenvironment activation to enhance safety; POWERbody for empowered efficacy with local activation; and the Dynamic Precision Library platform integrating computational biology and artificial intelligence. The company focuses on oncology, advancing a pipeline of monoclonal and bispecific antibodies such as ADG106, a CD137/4-1BB agonist for advanced solid tumors and non-Hodgkin's lymphoma; ADG116, a CTLA-4 antagonist enabling Treg depletion and soft ligand blocking; and ADG126 (muzastotug), the lead anti-CTLA-4 SAFEbody in Phase 1b/2 and Phase 2 trials for microsatellite stable colorectal cancer and other solids in combination with anti-PD-1 therapies. Founded in 2011 and headquartered in Suzhou Industrial Park, Jiangsu Province, China, Adagene conducts global research, development and clinical operations with partnerships spanning international organizations. Recent developments include a July 2025 strategic investment and option activation from Sanofi for up to $25 million to fund muzastotug's randomized Phase 2 trial in microsatellite stable colorectal cancer and a third SAFEbody discovery program, extending cash runway into 2027; a November 2025 licensing agreement with Third Arc Bio granting worldwide rights to two masked CD3 T cell engagers using SAFEbody technology for a $5 million upfront payment, up to $840 million in milestones and royalties, while retaining a no-cost option for Greater China, Singapore and South Korea; and a July 2025 partnering agreement with ConjugateBio for novel antibody-drug conjugates.
Company News
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene to Participate in Three Upcoming Investor Conferences
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types